ATC Group: L01XJ03 Glasdegib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01XJ03 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01X Other antineoplastic agents
4 L01XJ Hedgehog pathway inhibitors
5 L01XJ03

Active ingredients in L01XJ03

Active Ingredient Description
Glasdegib

Glasdegib is an inhibitor of the Hedgehog (Hh) signal transduction pathway that binds to Smoothened (SMO), a transmembrane protein, leading to decreased Glioma-Associated Oncogene (GLI) transcription factor activity and downstream pathway signalling. Hh pathway signalling is required for maintaining a leukaemic stem cell (LSC) population thus, glasdegib binding to and inhibiting SMO reduces GLI1 levels in AML cells and the leukaemic initiating potential of AML cells.

Related product monographs

Title Information Source Document Type  
DAURISMO Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
DAURISMO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

Finland (FI)

Ireland (IE)

Lithuania (LT)

Poland (PL)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.